The ACCOST-HH Trial:An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed

Link:
Autor/in:
Erscheinungsjahr:
2020
Medientyp:
Text
Lizenz:
  • info:eu-repo/semantics/restrictedAccess
Quellsystem:
Forschungsinformationssystem des UKE
Interne Metadaten
Quelldatensatz
oai:pure.atira.dk:publications/dafa5820-e4be-42eb-bb4a-54d86590631e